title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
74 Biggest Movers From Yesterday,20220429T091949,https://www.benzinga.com/news/22/04/26890965/74-biggest-movers-from-yesterday,JAZZ,0.023866,Neutral,0.007378
"Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More",20241121T171300,https://www.zacks.com/stock/news/2373588/biotech-stock-roundup-sage-incy-suffer-setbacks-jazz-wins-oncology-drug-approval-more,JAZZ,0.099683,Neutral,0.062317
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors - Impel Pharmaceuticals  ( NASDAQ:IMPL ) ,20230412T200100,https://www.benzinga.com/pressreleases/23/04/g31776707/impel-pharmaceuticals-announces-appointment-of-darren-cline-to-the-board-of-directors,JAZZ,0.027413,Neutral,0.0082
"Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In - Corbus Pharmaceuticals  ( NASDAQ:CRBP ) , AbbVie  ( NYSE:ABBV ) ",20240514T173240,https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38803783/will-pharma-and-healthcare-have-competitive-edge-in-cannabis-post-rescheduling-data,JAZZ,0.088964,Neutral,0.0
RedHill  ( RDHL )  Up on Orphan Drug Tag for NTM Disease Drug,20220818T150400,https://www.zacks.com/stock/news/1969750/redhill-rdhl-up-on-orphan-drug-tag-for-ntm-disease-drug,JAZZ,0.228073,Somewhat-Bullish,0.267771
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",20240111T220100,https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,JAZZ,0.025139,Neutral,0.019544
53 Biggest Movers From Yesterday,20220408T084938,https://www.benzinga.com/news/22/04/26539460/53-biggest-movers-from-yesterday,JAZZ,0.031907,Neutral,0.009724
38 Stocks Moving In Thursday's Mid-Day Session,20220407T171413,https://www.benzinga.com/news/22/04/26529716/38-stocks-moving-in-thursdays-mid-day-session,JAZZ,0.044051,Neutral,0.005025
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,JAZZ,0.020404,Neutral,0.130751
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors - Alkermes  ( NASDAQ:ALKS ) ,20230613T110000,https://www.benzinga.com/pressreleases/23/06/n32831446/alkermes-issues-letter-to-shareholders-highlighting-skills-and-experience-of-refreshed-board-of-di,JAZZ,0.019102,Neutral,0.0
"Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial",20220803T141314,https://www.benzinga.com/general/biotech/22/08/28331170/biotech-daily-mercks-two-combo-cancer-trials-miss-main-goal-approval-for-sinovacs-covid-19-shot-f,JAZZ,0.098659,Neutral,0.0
"The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study",20220607T123117,https://www.benzinga.com/general/biotech/22/06/27583701/the-daily-biotech-pulse-veru-seeks-emergency-use-nod-for-covid-19-therapy-vincerx-cuts-workforce-,JAZZ,0.10322,Neutral,0.009977
